PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35631379-5	2022	(3S)-vestitol 0.55 microM (V55) lowered NO release by 60% without altering cell viability and diminished IL-1beta, IL-1alpha, G-CSF, IL-10 and GM-CSF levels.	vestitol	5-13	interleukin 1 alpha	Mus musculus	105-113
35631379-5	2022	(3S)-vestitol 0.55 microM (V55) lowered NO release by 60% without altering cell viability and diminished IL-1beta, IL-1alpha, G-CSF, IL-10 and GM-CSF levels.	vestitol	5-13	interleukin 1 alpha	Mus musculus	115-124
35631379-5	2022	(3S)-vestitol 0.55 microM (V55) lowered NO release by 60% without altering cell viability and diminished IL-1beta, IL-1alpha, G-CSF, IL-10 and GM-CSF levels.	vestitol	5-13	colony stimulating factor 3 (granulocyte)	Mus musculus	126-131
35631379-5	2022	(3S)-vestitol 0.55 microM (V55) lowered NO release by 60% without altering cell viability and diminished IL-1beta, IL-1alpha, G-CSF, IL-10 and GM-CSF levels.	vestitol	5-13	interleukin 10	Mus musculus	133-138
35631379-5	2022	(3S)-vestitol 0.55 microM (V55) lowered NO release by 60% without altering cell viability and diminished IL-1beta, IL-1alpha, G-CSF, IL-10 and GM-CSF levels.	vestitol	5-13	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	143-149
29377427-5	2018	Our results showed that vestitol (IC20  = 214.7 muM) reduced the expression of genes enrolled with the alpha tubulin (fold -3.7), tubulin in microtubules (fold -3.7), and histone h3 (fold = -3.03), and that treatment with neovestitol (IC20  = 102.91 muM) downregulated prostaglandin E synthase gene (fold = -3.12), which are considered ideal targets for anticancer therapy.	vestitol	24-32	latexin	Homo sapiens	48-51
32114412-7	2020	Treatment with vestitol reduced GM-CSF, IL-6, TNF-alpha, IL-4 and TGF-beta levels and increased IL-10 release (P < 0.05).	vestitol	15-23	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	32-38
32114412-7	2020	Treatment with vestitol reduced GM-CSF, IL-6, TNF-alpha, IL-4 and TGF-beta levels and increased IL-10 release (P < 0.05).	vestitol	15-23	interleukin 6	Mus musculus	40-44
32114412-7	2020	Treatment with vestitol reduced GM-CSF, IL-6, TNF-alpha, IL-4 and TGF-beta levels and increased IL-10 release (P < 0.05).	vestitol	15-23	tumor necrosis factor	Mus musculus	46-55
32114412-7	2020	Treatment with vestitol reduced GM-CSF, IL-6, TNF-alpha, IL-4 and TGF-beta levels and increased IL-10 release (P < 0.05).	vestitol	15-23	interleukin 4	Mus musculus	57-61
32114412-7	2020	Treatment with vestitol reduced GM-CSF, IL-6, TNF-alpha, IL-4 and TGF-beta levels and increased IL-10 release (P < 0.05).	vestitol	15-23	transforming growth factor alpha	Mus musculus	66-74
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	cyclin G1	Mus musculus	142-147
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	calmodulin 1	Mus musculus	149-154
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	tumor necrosis factor (ligand) superfamily, member 15	Mus musculus	156-163
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	interleukin 11	Mus musculus	165-169
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	GATA binding protein 3	Mus musculus	171-176
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	growth arrest and DNA-damage-inducible 45 beta	Mus musculus	178-185
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	cyclin-dependent kinase inhibitor 1B	Mus musculus	187-193
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	colony stimulating factor 1 (macrophage)	Mus musculus	195-199
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	chemokine (C-C motif) ligand 5	Mus musculus	201-205
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	baculoviral IAP repeat-containing 3	Mus musculus	207-212
32114412-8	2020	Vestitol affected the expression of genes related to NF-kappaB pathway, NO synthase, and inhibition of leukocyte transmigration, namely: Ccs, Ccng1, Calm1, Tnfsf15, Il11, Gata3, Gadd45b, Cdkn1b, Csf1, Ccl5, Birc3 (negatively regulated), and Igf1 (positively regulated).	vestitol	0-8	insulin-like growth factor 1	Mus musculus	241-245
32114412-9	2020	Vestitol diminished the activation of NF-kappaB and Erk 1/2 pathways and induced macrophages into M2-like polarization.	vestitol	0-8	mitogen-activated protein kinase 3	Mus musculus	52-59
32114412-10	2020	The modulatory effects of vestitol are due to inhibition of NF-kappaB and Erk 1/2 signaling pathways, which are associated with the production of pro-inflammatory factors.	vestitol	26-34	mitogen-activated protein kinase 3	Mus musculus	74-81
29377427-5	2018	Our results showed that vestitol (IC20  = 214.7 muM) reduced the expression of genes enrolled with the alpha tubulin (fold -3.7), tubulin in microtubules (fold -3.7), and histone h3 (fold = -3.03), and that treatment with neovestitol (IC20  = 102.91 muM) downregulated prostaglandin E synthase gene (fold = -3.12), which are considered ideal targets for anticancer therapy.	vestitol	24-32	latexin	Homo sapiens	250-253
26938776-3	2016	Pre-treatment with vestitol at 1, 3, or 10 mg/kg reduced LPS- or mBSA-induced neutrophil migration and the release of CXCL1/KC and CXCL2/MIP-2 in vivo.	vestitol	19-27	chemokine (C-X-C motif) ligand 1	Mus musculus	118-123
26938776-3	2016	Pre-treatment with vestitol at 1, 3, or 10 mg/kg reduced LPS- or mBSA-induced neutrophil migration and the release of CXCL1/KC and CXCL2/MIP-2 in vivo.	vestitol	19-27	chemokine (C-X-C motif) ligand 2	Mus musculus	131-136
26938776-3	2016	Pre-treatment with vestitol at 1, 3, or 10 mg/kg reduced LPS- or mBSA-induced neutrophil migration and the release of CXCL1/KC and CXCL2/MIP-2 in vivo.	vestitol	19-27	chemokine (C-X-C motif) ligand 2	Mus musculus	137-142
26938776-4	2016	Likewise, pre-treatment with vestitol at 1, 3, or 10 muM reduced the levels of CXCL1/KC and CXCL2/MIP-2 in macrophage supernatants in vitro.	vestitol	29-37	chemokine (C-X-C motif) ligand 1	Mus musculus	79-84
26938776-4	2016	Likewise, pre-treatment with vestitol at 1, 3, or 10 muM reduced the levels of CXCL1/KC and CXCL2/MIP-2 in macrophage supernatants in vitro.	vestitol	29-37	chemokine (C-X-C motif) ligand 2	Mus musculus	92-97
26938776-4	2016	Likewise, pre-treatment with vestitol at 1, 3, or 10 muM reduced the levels of CXCL1/KC and CXCL2/MIP-2 in macrophage supernatants in vitro.	vestitol	29-37	chemokine (C-X-C motif) ligand 2	Mus musculus	98-103
26938776-7	2016	With regard to the activity of vestitol on neutrophils isolated from the bone marrow of mice, there was a reduction on the chemotaxis of CXCL2/MIP-2 or LTB4-induced neutrophils and on calcium influx after pre-treatment with the compound at 3 or 10 muM.	vestitol	31-39	chemokine (C-X-C motif) ligand 2	Mus musculus	137-142
26938776-7	2016	With regard to the activity of vestitol on neutrophils isolated from the bone marrow of mice, there was a reduction on the chemotaxis of CXCL2/MIP-2 or LTB4-induced neutrophils and on calcium influx after pre-treatment with the compound at 3 or 10 muM.	vestitol	31-39	chemokine (C-X-C motif) ligand 2	Mus musculus	143-148